Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer

BJU International

Volumn 103, Issue 6, 2009, Pages 726-729

  Horvath, Andras ^a   Mostafid, Hugh ^a  

^a NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Intermediate risk; Risk groups; Therapy

Indexed keywords

BCG VACCINE; MITOMYCIN C; OFLOXACIN; PLACEBO;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DEVICE; HIGH RISK POPULATION; HUMAN; PHOTODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 61349177826     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08094.x     Document Type: Review

References (20)

1. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer. 15-year outcome. J Urol 1997 158 : 62 7
2. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol 2006 49 : 466 77
3. Jones HC, Swinney J. Thiotepa in treatment of tumours of the bladder. Lancet 1961 16 : 615 8
4. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976 116 : 180 3
5. Lamm DL, Blumestein BA, Crissman JD et al. Maintenance baciluus Calmette-Guerin immunotherapy for recurrent TA,T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomised Southwest Oncology Group Study. J Urol 2000 163 : 1124 9
6. Malkowicz SB, Nichols P, Lieskovsky G et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990 144 : 641 5
7. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta analysis of published Results of randomized clinical trials. J Urol 2004 171 : 2186 90
8. Hall RR, Parmar MK, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994 308 : 257 60
9. EAU. Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. Available at: http://www.uroweb.org/fileadmin/user-upload/guidelines/ tat1%20bladder%20cancer.pdf. Accessed April 2008
10. BAUS (Multi-disciplinary Team). Guidance for Managing Bladder Cancer. Available at: http://www.bauslibrary.co.uk/pdfs/bsonc/ mdt%20guidance%20for%20bladder%20cancer.pdf. Accessed April 2008
11. Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. J Urol 2007 178 : 2314 30
12. Oosterlinck W, Solsona E. Low grade, Ta (noninvasive) urothelial carcinoma of the bladder. In Soloway M, Carmack A, Khoury S, Bladder Tumors, 1st edn. Paris : Health Publication Ltd, 2006 : 157 9
13. Kyowa Hakko. Summary of Product Characteristics. Mitomycin-C Kyowa. Slough, Berks, UK : Kyowa Hakko (UK) Limited
14. Friedrich MG, Pichlmeier U, Schwaibold H et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder carcinoma Eur Urol 2007 52 : 1123 30
15. Au JL, Baladament RA, Wientjes MG et al. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: Results of a randomised phase III trial. J Natl Cancer Inst 2001 93 : 597 604
16. Fernandez-Gomez J, Solsona E, Martinez-Pinero L et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guèrin. Multivariate analysis of data from four randomized CUETO Trials. Eur Urol 2008 53 : 992 1002
17. Ali-El-Dein B, Sarhan O, Nabeeh A et al. Maintenance intravesical BCG therapy for superficial bladder tumours: 3 week multiple courses versus monthly doses. J Urol 2007 177 : 522, Abstract 1579
18. Colombel M, Saint F, Chopin D et al. The effects of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomised, prospective, double-blind, placebo controlled, multicentre study. J Urol 2006 176 : 935 9
19. DiStasi SM, Giannantoni A, Giuriolo A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006 7 : 43 51
20. Denzinger S, Wieland WE, Otto W et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomised study. BJU Int 2008 101 : 566 9